Segment Wealth Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 142,198 shares of the biopharmaceutical company’s stock after acquiring an additional 1,651 shares during the quarter. Pfizer makes up approximately 1.2% of Segment Wealth Management LLC’s investment portfolio, making the stock its 14th largest position. Segment Wealth Management LLC’s holdings in Pfizer were worth $5,159,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the business. Ballew Advisors Inc acquired a new position in shares of Pfizer during the 1st quarter worth approximately $102,000. Earnest Partners LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Pfizer during the 4th quarter worth approximately $118,000. Delpha Capital Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $126,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in shares of Pfizer during the 1st quarter worth approximately $132,000. 69.12% of the stock is owned by institutional investors.
In related news, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the transaction, the vice president now directly owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sally Susman sold 40,381 shares of the stock in a transaction on Friday, July 20th. The shares were sold at an average price of $37.22, for a total value of $1,502,980.82. Following the completion of the transaction, the insider now directly owns 155,377 shares of the company’s stock, valued at $5,783,131.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is owned by corporate insiders.
NYSE PFE opened at $42.20 on Friday. Pfizer Inc. has a one year low of $33.20 and a one year high of $42.77. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market capitalization of $249.13 billion, a P/E ratio of 15.92, a PEG ratio of 2.01 and a beta of 0.96.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. During the same period in the prior year, the company earned $0.67 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.22%. The ex-dividend date was Thursday, August 2nd. Pfizer’s dividend payout ratio is currently 51.32%.
PFE has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Monday, May 14th. Credit Suisse Group reaffirmed a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Friday, May 18th. Societe Generale reaffirmed a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Wednesday, May 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Thursday, June 7th. They set an “overweight” rating and a $45.00 target price for the company. Finally, Morgan Stanley reaffirmed a “buy” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, June 11th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $41.89.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Index Funds
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.